Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Momenta Delays on Adalimumab In A Bid To Save On Costs

Executive Summary

US filing previously slated for the current quarter is pushed back to an undisclosed date, with costs in mind; Momenta also plans to raise up to US$177.5 million through public offering.

You may also be interested in...

Eylea Biosimilar Developer Momenta To Be Acquired By J&J For $6.5bn

Momenta Pharmaceuticals has signed an agreement to be acquired by Johnson & Johnson, with the deal to include, for now, the M710 biosimilar aflibercept candidate being developed with Mylan.

Teva, Sandoz, Mylan, Pfizer…Who Sees Value In The US Biosimilars Market?

While 2018 was a record year for US biosimilar approvals and launches, companies are still struggling for market share in certain therapies and facing obstacles in getting their products over the line. Generics Bulletin rounds up where the leading players stand, ahead of financial results being published in the coming days and weeks.

Teva Among Beneficiaries As Bystolic Antitrust Case Dismissed

Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts